What is Clinical Research?
Memorial Healthcare Clinical Research works with Memorial Healthcare Institute for Neuroscience and other Memorial Healthcare departments offering clinical research trials for our patients.
Participating in a clinical trial may give you access to experimental, cutting edge treatment options. Today people are receiving better treatments that are the result of past clinical trials. Through clinical trials, doctors determine whether new treatments are safe and effect and work better than current treatments. Clinical trials are the key to making progress against neurological diseases.
Clinical Research at Memorial Healthcare
Memorial Healthcare Institute for Neuroscience is currently conducting clinical trials for Multiple Sclerosis and Migraine Headaches. If you or someone you know is interested in learning more about clinical trials at the Memorial Healthcare Institute for Neuroscience, please contact our Clinical Research Department at 989-729-4133 or email us at Research@MemorialHealthcare.org.
Research Opportunity
We are currently offering Neurofiliment Light (NfL) Chain research opportunities utilizing Quanterix SIMOA technology, the gold standard in today’s research field.
To learn more please click here for a flyer. For more information, please contact Amber Decker, B.S., Clinical Research Lab Coordinator at (989) 725-9424, ext. 4033 or 1-800-206-8706, ext. 4033 or via email at ADecker@MemorialHealthcare.org.
CURRENT CLINICAL RESEARCH TRIALS
| Study Protocol # | Protocol Title | Status |
|---|---|---|
| COMB157GUS09 | A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation | Recruitment Open |
| GN42272 | Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS) | Recruitment Open |
| CLOU064C12302 | Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS | Recruitment Open |
| 7033093STR3001 | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Recruitment Open |
| 232SM303 | A Study to Evaluate Higher Dose (HD) Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Previously Treated With Risdiplam | Recruitment Opening Soon |
| NMOSD-750 | CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD) | Recruitment Opening Soon |
| CN42097 | A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis | Active, Recruitment Closed at Site |
| MS700568_0079 | A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) | Active, Recruitment Closed at Site |
| EFC16033 | Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168 | Active, Recruitment Closed at Site |
| EFC16035 | Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) | Active, Recruitment on FDA Hold |
| Exact Sciences 2021-05 | Specimen Collection Study to Evaluate Biomarkers in Subjects with Cancer | Recruitment Opening Soon |
| J1G-MC-LAKD | Assessment of safety and efficacy of subcutaneous remternetug in early symptomatic Alzheimer’s disease | Recruitment Opening Soon |
| WN43194 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) | Recruitment Opening Soon |
| J1G-MC-LAKF | Assessment of safety and efficacy of intravenous remternetug in early symptomatic Alzheimer’s disease | Recruitment Expected to Open Fall 2023 |
